High-dose methotrexate with or without whole brain radiotherapy for primary CNS lymphoma (G-PCNSL-SG-1): a phase 3, randomised, non-inferiority trial-Reference-Cited by-同舟云学术

High-dose methotrexate with or without whole brain radiotherapy for primary CNS lymphoma (G-PCNSL-SG-1): a phase 3, randomised, non-inferiority trial

Published:2010-11 Issue:11 Volume:11 Page:1036-1047
ISSN:1470-2045
Container-title:The Lancet Oncology
language:en
Short-container-title:The Lancet Oncology

Author:

Thiel Eckhard,Korfel Agnieszka,Martus Peter,Kanz Lothar,Griesinger Frank,Rauch Michael,Röth Alexander,Hertenstein Bernd,von Toll Theda,Hundsberger Thomas,Mergenthaler Hans-Günther,Leithäuser Malte,Birnbaum Tobias,Fischer Lars,Jahnke Kristoph,Herrlinger Ulrich,Plasswilm Ludwig,Nägele Thomas,Pietsch Torsten,Bamberg Michael,Weller Michael

Publisher

Elsevier BV

Subject

Oncology

Reference38 articles.

1. Primary central nervous system lymphoma: biological aspects and controversies in management;Bessell;Eur J Cancer,2007

2. Treatment of primary central nervous system lymphoma;Ekenel;Curr Treat Options Neurol,2007

3. Primary CNS lymphoma;Gerstner;Expert Rev Anticancer Ther,2007

4. Treatment options for central nervous system lymphomas in immunocompetent patients;Jahnke;Expert Rev Neurother,2009

5. Therapeutic challenges in primary CNS lymphoma;Morris;Lancet Neurol,2009

Cited by 517 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

2. Sequential high‐dose methotrexate and cytarabine administration improves outcomes in real‐world patients with primary central nervous system lymphoma: A report from the Australasian Lymphoma Alliance;eJHaem;2024-06-21

3. Diagnostics and treatment delay in primary central nervous system lymphoma: What the neurosurgeon should know;Acta Neurochirurgica;2024-06-11

4. Primary central nervous system lymphomas: EHA–ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up;Annals of Oncology;2024-06

5. Primary central nervous system lymphomas: EHA–ESMO Clinical Practice Guideline for diagnosis, treatment and follow‐up;HemaSphere;2024-06